Immediate Impact
63 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
2024 Standout
Works of Li Ma being referenced
The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy
2014
Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer
2013
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Li Ma | 500 | 192 | 236 | 412 | 288 | 94 | 1.2k | |
| Mauro Loi | 674 | 275 | 199 | 297 | 561 | 119 | 1.5k | |
| L. Claude | 885 | 195 | 257 | 499 | 266 | 100 | 1.5k | |
| Jean‐Baptiste Guy | 439 | 144 | 383 | 267 | 428 | 89 | 1.4k | |
| Kazuo Kubota | 400 | 140 | 173 | 397 | 316 | 61 | 1.1k | |
| Carmen Stromberger | 473 | 268 | 278 | 255 | 365 | 81 | 1.6k | |
| Cecilia Menna | 830 | 304 | 207 | 290 | 347 | 94 | 1.4k | |
| Ji Hyun Chang | 287 | 144 | 189 | 229 | 347 | 83 | 1.1k | |
| Hubing Wu | 324 | 330 | 160 | 519 | 468 | 93 | 1.3k | |
| Pedram Heidari | 203 | 221 | 257 | 293 | 279 | 70 | 1.1k | |
| Sho Matsubara | 310 | 203 | 300 | 287 | 124 | 95 | 1.4k |
All Works
Login with ORCID to disown or claim papers
Loading papers...